Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-0299685 for Menopausal Vasomotor Symptoms
NCT00314964Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing PD-0299685 with Placebo (2 arms). Primary endpoint: Effectiveness of PD-0299685 in reducing both the frequency and severity of vasomotor symptoms at 12 weeks. Started Aug 2006; status: completed.
02
Drugs
PD-0299685
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00314964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314964.